Medtronic MDT Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Cardiovascular | $13.98B+3.4% | $13.51B+3.2% | $13.09B+2.6% | $12.76B+2.2% | $12.48B+1.7% | |
| Diabetes | $3.11B+3.7% | $3B+3.5% | $2.9B+2.5% | $2.83B+2.7% | $2.76B+2.6% | |
| Medical Surgical | $8.81B+2.0% | $8.64B+1.2% | $8.54B+0.5% | $8.49B+1.0% | $8.41B+0.2% | |
| Neuroscience | $10.29B+1.3% | $10.16B+1.0% | $10.06B+1.1% | $9.95B+1.0% | $9.85B+0.8% | |
| Other Operating Segments | $135M-0.4% | $135.5M-0.4% | $136M-0.4% | $136.5M-0.4% | $137M-13.3% | |
| Reportable segment operating profit by Business | ||||||
| Cardiovascular | $3.67B+3.2% | $3.56B+2.0% | $3.49B+2.8% | $3.39B+1.4% | $3.34B+40.0% | |
| Medical Surgical | $2.13B+1.4% | $2.1B-0.6% | $2.11B+0.3% | $2.11B+1.7% | $2.07B+38.4% | |
| Neuroscience | $3.06B+0.7% | $3.04B-0.8% | $3.07B+0.5% | $3.05B+0.6% | $3.03B+39.5% | |
| Other segment items by Business | ||||||
| Cardiovascular | -$47M+21.7% | -$60M0.0% | -$60M-20.0% | -$50M-22.0% | -$41M-20.6% | |
| Medical Surgical | $14M+7.7% | $13M+18.2% | $11M-21.4% | $14M-22.2% | $18M+10.8% | |
| Neuroscience | $36M+2.9% | $35M0.0% | $35M+59.1% | $22M-29.0% | $31M+17.0% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Cardiovascular | $4.69B+3.2% | $4.55B+4.5% | $4.35B+2.0% | $4.27B+3.2% | $4.14B+3.8% | |
| Medical Surgical | $3.48B+2.8% | $3.38B+2.4% | $3.3B+0.4% | $3.29B+1.1% | $3.26B+2.5% | |
| Neuroscience | $3.15B+1.8% | $3.1B+3.4% | $2.99B+1.1% | $2.96B+2.2% | $2.9B+3.5% | |
| Selling, general, and administrative expense by Business | ||||||
| Cardiovascular | $4.52B+4.1% | $4.34B+2.8% | $4.23B+3.0% | $4.1B+2.0% | $4.02B+0.9% | |
| Medical Surgical | $2.51B+2.3% | $2.45B+0.9% | $2.43B+0.7% | $2.41B+0.6% | $2.4B-0.3% | |
| Neuroscience | $3.42B+1.8% | $3.36B+0.6% | $3.34B+1.2% | $3.3B+0.7% | $3.28B+0.6% | |
| Currency translation and other by Business | ||||||
| Other Operating Segments | $0-100% | $250K-50.0% | $500K-33.3% | $750K-25.0% | $1M— | |
| Depreciation by Business | ||||||
| Cardiovascular | $253M+3.7% | $244M+4.3% | $234M0.0% | $234M+4.0% | $225M+3.8% | |
| Medical Surgical | $225M+1.4% | $222M+5.2% | $211M+1.0% | $209M+2.5% | $204M+2.3% | |
| Neuroscience | $321M+4.2% | $308M+2.3% | $301M+2.7% | $293M+4.3% | $281M+3.3% | |
| Research and development expense by Business | ||||||
| Cardiovascular | $1.14B+1.2% | $1.12B+3.3% | $1.09B+4.1% | $1.04B+2.3% | $1.02B+1.1% | |
| Medical Surgical | $687M-0.9% | $693M+1.5% | $683M+1.5% | $673M+1.1% | $666M+1.1% | |
| Neuroscience | $616M-1.6% | $626M+0.2% | $625M+1.5% | $616M+0.7% | $612M-1.1% | |
| Net Sales by Geography | ||||||
| Ireland | $143M+6.7% | $134M+6.3% | $126M+5.0% | $120M+2.6% | $117M+2.6% | |
| Rest of world | $18.12B+3.1% | $17.57B+2.7% | $17.11B+2.0% | $16.77B+3.2% | $16.25B+0.8% | |
| United States | $18.1B+1.8% | $17.78B+1.5% | $17.52B+1.2% | $17.31B+0.8% | $17.17B+1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medtronic break its business down?
- Medtronic (MDT) reports net sales by business across 6 parts — Cardiovascular, Diabetes, Medical Surgical, Neuroscience and Other operating segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Medtronic's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medtronic's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
